Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Beginning Cash Balance: 2010-2025

Historic Beginning Cash Balance for Ironwood Pharmaceuticals (IRWD) over the last 16 years, with Sep 2025 value amounting to $92.9 million.

  • Ironwood Pharmaceuticals' Beginning Cash Balance fell 12.01% to $92.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $88.2 million, marking a year-over-year decrease of 20.86%. This contributed to the annual value of $92.2 million for FY2024, which is 85.99% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Beginning Cash Balance stood at $92.9 million for Q3 2025, which was down 14.41% from $108.5 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Beginning Cash Balance ranged from a high of $740.8 million in Q2 2023 and a low of $88.2 million during Q4 2024.
  • In the last 3 years, Ironwood Pharmaceuticals' Beginning Cash Balance had a median value of $108.5 million in 2025 and averaged $216.5 million.
  • In the last 5 years, Ironwood Pharmaceuticals' Beginning Cash Balance surged by 104.81% in 2021 and then crashed by 85.96% in 2024.
  • Quarterly analysis of 5 years shows Ironwood Pharmaceuticals' Beginning Cash Balance stood at $574.3 million in 2021, then declined by 0.02% to $574.2 million in 2022, then slumped by 80.59% to $111.5 million in 2023, then dropped by 20.86% to $88.2 million in 2024, then dropped by 12.01% to $92.9 million in 2025.
  • Its last three reported values are $92.9 million in Q3 2025, $108.5 million for Q2 2025, and $88.6 million during Q1 2025.